Evidence map›Paper›PMID 25952768›Full record

ArticleAIDS and behavior2016

Self-Reported HIV and HCV Screening Rates and Serostatus Among Substance Abuse Treatment Patients.

Diana Hernández, Daniel J Feaster, Lauren Gooden, Antoine Douaihy, Raul Mandler, Sarah J Erickson, Tiffany Kyle, Louise Haynes, Robert Schwartz, Moupali Das and 1 more

Abstract read
In one paragraph

Article in AIDS and behavior, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 5 papers.

0numbers the graph read from it
0cells of the map it votes in
5citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

5 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Estimating Individual Treatment Effect in Observational Data Using Random Forest Methods.Journal of computational and graphical statistics : a joint publication of American Statistical Association, Institute of Mathematical Statistics, Interface Foundation of North America · 2018
    Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors.

Diana HernándezDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 W. 168th St, Rm 934, New York, NY, 10032, USA. dh2494@columbia.edu.
Daniel J FeasterMiller School of Medicine, University of Miami, Miami, FL, USA.
Lauren GoodenDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 W. 168th St, Rm 934, New York, NY, 10032, USA.
Antoine DouaihyUniversity of Pittsburgh Medical Center, Pittsburgh, PA, USA.
Raul MandlerNational Institute on Drug Abuse, Bethesda, MD, USA.
Sarah J EricksonDepartment of Psychology, University of New Mexico, Albuquerque, NM, USA.
Tiffany KyleThe Center for Drug Free Living, Orlando, FL, USA.
Louise HaynesMedical University of South Carolina, Charleston, SC, USA.
Robert SchwartzFriends Research Institute, Baltimore, MD, USA.
Moupali DasSchool of Medicine, University of California, San Francisco, San Francisco, USA.
Lisa MetschDepartment of Sociomedical Sciences, Mailman School of Public Health, Columbia University, 722 W. 168th St, Rm 934, New York, NY, 10032, USA.

Funding

FLORIDA NODE OF THE DRUG ABUSE CLINICAL TRIALS NETWORKU10DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI METSCH, LISA R, SZAPOCZNIK, JOSE · 2000 to 2015
$56.9M
The Florida Node Alliance of the National Drug Abuse Treatment Clinical Trials NetworkUG1DA013720 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI Daniel J Feaster, Viviana Elizabeth Horigian · 2015 to 2026
$50.6M
The Statistics, Data Science, and Data Management (SDM) CoreP30MH043520 · NIMH · NEW YORK STATE PSYCHIATRIC INSTITUTE DBA RESEARCH FOUNDATION FOR MENTAL HYGIENE, INC · PI MILTON L WAINBERG · 2003 to 2026
$48.2M
Clinical Trials Network, Ohio Valley Node U10DA013732U10DA013732 · NIDA · UNIVERSITY OF CINCINNATI · PI WINHUSEN, T JOHN · 2000 to 2015
$45.0M
Southern Consortium Node of the Clinical Trials NetworkU10DA013727 · NIDA · MEDICAL UNIVERSITY OF SOUTH CAROLINA · PI BRADY, KATHLEEN T. · 2000 to 2015
$34.4M
Western States Node of the National Drug Abuse Treatment Clinical Trials NetworkU10DA015815 · NIDA · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · PI MCCARTY, DENNIS, SORENSEN, JAMES L · 2002 to 2015
$25.2M
CLINICAL TRIALS NETWORK MID-ATLANTIC COLLABORATIVE GROUPU10DA013034 · NIDA · JOHNS HOPKINS UNIVERSITY · PI SCHWARTZ, ROBERT P, STITZER, MAXINE L · 1999 to 2015
$25.2M
Clinical Trials Network: Southwest NodeU10DA015833 · NIDA · UNIVERSITY OF NEW MEXICO · PI MCCRADY, BARBARA S · 2002 to 2014
$19.9M
OREGON NODE - NATIONAL CLINICAL TRIALS NETWORKU10DA013036 · NIDA · OREGON HEALTH & SCIENCE UNIVERSITY · PI MCCARTY, DENNIS · 1999 to 2010
$18.5M
CLINICAL TRIALS NETWORK: NEW ENGLAND NODEU10DA013038 · NIDA · YALE UNIVERSITY · PI CARROLL, KATHLEEN M. · 1999 to 2010
$17.3M
CLINICAL TRIAL RESEARCH PROJECT COREU10DA020036 · NIDA · UNIVERSITY OF PITTSBURGH AT PITTSBURGH · PI DALEY, DENNIS C · 2005 to 2015
$14.1M
HIV Testing and Counseling in STD Clinics: an Adaptation of CTN 0032RC2DA028973 · NIDA · UNIVERSITY OF MIAMI SCHOOL OF MEDICINE · PI FEASTER, DANIEL J · 2009 to 2010
$12.3M
NIDA NIH HHS HHSN271200522071CNIDA NIH HHS RC2 DA028973NIDA NIH HHS U10 DA013034NIDA NIH HHS U10 DA013036NIDA NIH HHS U10 DA013038NIDA NIH HHS U10DA013038NIDA NIH HHS U10 DA013720NIDA NIH HHS U10DA013720NIDA NIH HHS U10 DA013727NIDA NIH HHS U10 DA013732NIDA NIH HHS U10DA013732NIDA NIH HHS U10 DA015815NIDA NIH HHS U10 DA015833NIDA NIH HHS U10DA015833NIDA NIH HHS U10 DA020036NIDA NIH HHS U10DA020036NIDA NIH HHS U10DA13034NIDA NIH HHS U10DA13036NIDA NIH HHS U10DA13720-09SNIDA NIH HHS U10DA13727NIDA NIH HHS U10DA15815NIDA NIH HHS UG1 DA013034NIDA NIH HHS UG1 DA013720NIMH NIH HHS P30 MH043520
6 · The paper itself

Abstract

Substance users are at increased risk for HIV and HCV infection. Still, many substance use treatment programs (SUTP) fail to offer HIV/HCV testing. The present secondary analysis of screening data from a multi-site randomized trial of rapid HIV testing examines self-reported HIV/HCV testing patterns and serostatus of 2473 SUTP patients in 12 community-based sites that had not previously offered on-site testing. Results indicate that most respondents screened for the randomized trial tested more than a year prior to intake for HIV (52 %) and HCV (38 %). Prevalence rates were 3.6 and 30 % for HIV and HCV, respectively. The majority of participants that were HIV (52.2 %) and HCV-positive (40.5 %) reported having been diagnosed within the last 1-5 years. Multivariable logistic regression showed that members of high-risk groups were more likely to have tested. Bundled HIV/HCV testing and linkage to care issues are recommended for expanding testing in community-based SUTP settings.

Indexed as

Self ReportDrug UsersFemaleHepatitis CHIV InfectionsHIV SeronegativityHIV SeropositivityHIV SeroprevalenceHumansLogistic ModelsMaleMass ScreeningMiddle AgedPrevalenceSexual BehaviorSubstance Abuse, IntravenousCommunity based substance abuse treatment programsHIV/HCV sceening and serostatusHIV/HCV testing and linkage to careSubstance abuse treatment patients

Identifiers

PMID25952768
PMCPMC4637257

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.